CLOs on the Move

Harborchase-Sterling Heights

www.courtyardmanor.com

 
Harborchase-Sterling Heights is a Sterling Heights, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Jigaw Health

Jigaw Health is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Texas Healthcare PLLC

Texas Healthcare PLLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Fort Worth, TX. To find more information about Texas Healthcare PLLC, please visit www.txhealthcare.com

Swift Medical

Swift Medical is the world leader in digital wound care management, delivering advanced wound care visualization and touchless 3D measurement through its smartphone-ready Swift Skin and Wound software. Swift`s enterprise-grade solution streamlines clinical and administrative wound care management workflows, from image capture and automatic risk scoring to assessment scheduling and claims submission. Today, Skin and Wound has been adopted by more than 4,000 facilities to monitor over 100,000 beds.

Lively

Lively provides hearing devices from the convenience of your home, all under the guidance of a doctor for 50% less than the national average.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.